Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
Jan Van Elslande, Matthijs Oyaert, Natalie Lorent, et al.
Diagnostic Microbiology and Infectious Disease (2022) Vol. 103, Iss. 1, pp. 115659-115659
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing
Mary K. Hayden, Ibrahim K El Mikati, Kimberly E. Hanson, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 61
Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)
Miller Jm, Matthew J. Binnicker, Sheldon Campbell, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 46
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 4, pp. 351-360
Closed Access | Times Cited: 41
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 35
IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
Bram Decru, Jan Van Elslande, Sophie Steels, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
Testing for SARS-CoV-2: lessons learned and current use cases
Elitza S. Theel, James E. Kirby, Nira R. Pollock
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 5
Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response
Charles O. Noble, Ellie McDonald, Suellen Nicholson, et al.
Journal of Infection (2025), pp. 106436-106436
Open Access
Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity
Simon Merkt, Solomon Ali, Esayas Kebede Gudina, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection
Mariam Movsisyan, Nune Truzyan, И. Э. Каспарова, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
SARS‐CoV‐2 seroprevalence among blood donors in Uganda: 2019–2022
Evan M. Bloch, Dorothy Kyeyune, Jodie L. White, et al.
Transfusion (2023) Vol. 63, Iss. 7, pp. 1354-1365
Open Access | Times Cited: 10
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
Lawrence T. Reiter, Johann Greffrath, Bian Zidel, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Protective effectiveness of prior SARS-CoV-2 infection and hybrid immunity against Omicron infection and severe disease: a systematic review and meta-regression
Niklas Bobrovitz, Harriet Ware, Xiaomeng Ma, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 17
Trajectory and Demographic Correlates of Antibodies to SARS-CoV-2 Nucleocapsid in Recently Infected Blood Donors, United States
James M. Haynes, Roger Y. Dodd, Lauren A. Crowder, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 7
Open Access | Times Cited: 9
Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome
Christopher Hackenbruch, Yacine Maringer, Christian M. Tegeler, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 701-701
Open Access | Times Cited: 8
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults
Gro Tunheim, Even Fossum, Anna Hayman Robertson, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
The humoral immune response more than one year after SARS-CoV-2 infection: low detection rate of anti-nucleocapsid antibodies via Euroimmun ELISA
Gregor Paul, Philipp Strnad, Oliver Wienand, et al.
Infection (2022) Vol. 51, Iss. 1, pp. 83-90
Open Access | Times Cited: 12
Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses
Tim Westphal, Maria Mader, Hendrik Karsten, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
SARS-CoV-2–Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19
Zachary S. Orban, Lavanya Visvabharathy, Gina S. Perez Giraldo, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 6
Open Access | Times Cited: 6
Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave
Maja Sočan, Katarina Prosenc, Maja Mrzel
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 4, pp. 3665-3665
Open Access | Times Cited: 5
Exploring cell-free assays for COVID-19 serosurvey
Lucia Inchauste, Elif Nurtop, Nadége Brisbarre, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Humoral immunity across the SARS-CoV-2 Spike after Sputnik V (Gam‑COVID‑Vac) vaccination
Alejandro Cornejo, Christopher Franco, Mariajosé Rodríguez, et al.
(2024)
Open Access | Times Cited: 1
Clinical and serological predictors of post COVID-19 condition–findings from a Canadian prospective cohort study
Erin Collins, Yannick Galipeau, Corey Arnold, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 1
Humoral Immunity across the SARS-CoV-2 Spike after Sputnik V (Gam-COVID-Vac) Vaccination
Alejandro Cornejo, Christopher Franco, Mariajosé Rodríguez, et al.
Antibodies (2024) Vol. 13, Iss. 2, pp. 41-41
Open Access | Times Cited: 1
Durability of Humoral Responses after an Adapted SARS-CoV-2 mRNA Vaccine Dose in Hemodialysis Patients
Louise Benning, Marie Bartenschlager, Heeyoung Kim, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 738-738
Open Access | Times Cited: 1
COVID-19 in kidney transplantation-implications for immunosuppression and vaccination
Lavanya Kodali, Pooja Budhiraja, Juan Gea‐Banacloche
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top